Orange County Business Journal’s Post

NeuroOne® (Nasdaq: NMTC) Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update. Dave Rosa, CEO of NeuroOne, commented, “We made excellent progress this quarter across multiple fronts. Revenue growth continued regarding our sEEG product line as new customer sites were added by Zimmer Biomet. We also initiated the limited commercial launch of the OneRF™ Ablation System, an exciting accomplishment given we are the first company to receive FDA 510(k) clearance to market this novel technology in the United States. Customer interest has been strong and we believe the OneRF™ Ablation System, with combination diagnostic and therapeutic functionality, has the capability to create a paradigm shift in neurosurgical procedures. Moving forward, we will investigate other applications to leverage our ablation system. We continue to believe strongly in the market opportunity for our drug delivery system as we believe it has the potential to create a unique platform for both identifying the target area in the brain, delivering the pharmacologic agent and monitoring its performance.” Read the press release for more information here: https://lnkd.in/dqF3R7r5 #N1MTC #NeuroOne #businessupdate

#RegenerativeMedicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured firm commitments for a strategic placement amounting to A$3.5 million at A$0.37 per share. The placement has attracted significant interest from prominent investors including Chris Ellison, Rod Jones, Michael Malone, the McCusker Family and the Merchant Biotech Fund, thereby bolstering the company's share register. The placement will result in the issuance of 9,459,460 new fully paid ordinary shares, with allotment expected on February 28. With this cash injection, the company is now poised to advance its Striate+ bone repair and Remplir nerve repair products in global markets, focusing on a strategic regulatory program and the completion of a pivotal nerve repair study for US regulatory approval in 2024. More at #Proactive #ProactiveInvestors #ASX #OTC #OCC #ORHHF #Biotech #Medicine #CellTherapy http://ow.ly/RlHy105jm05

Zynex Medical (Nasdaq: ZYXI) Chairman and CEO, Thomas Sandgaard, joined Steve Darling from Proactive Investors to discuss Zynex's significant growth and innovations. Key Highlights - Q2 2024 Revenue Increased 11% to $49.9 Million - Q2 2024 orders increased 20% year-over-year, the highest number of orders in Company history for the ninth consecutive quarter. - Year-to-date cash flow from operations of $3.2 Million, a 20% year-over-year increase. - Zynex repurchased $2.2 Million of the company's common stock in Q2 2024. Zynex's innovations include next-generation pain management devices and a new pulse oximeter, as the company aims to diversify its product offerings and capture significant market share. For more details, you can watch the entire interview and read the article by clicking the link below. https://lnkd.in/ebxBiuUQ

Going to the CRS Annual Meeting & Expo, in Bologna, Italy? Make sure to stop by and listen to Dr. Yang Su discuss manufacturing Nanoparticle Albumin Bound (nab) technology! With fewer side-effects than traditional systems, nanoparticle albumin bound (Nab) drug delivery is a critically important aspect in chemotherapy medication and manufacturing this drug delivery must address many challenges. Drop by Booth 64 and speak to Dr. Su. If you are unable to attend this conference, learn more about nab at: https://hubs.la/Q02DrYz-0 #Microfluidics #Microfluidizerprocessors #Microfluidizertechnology #nab #nanoparticles #nanoparticlesalbuminboundtechnology #2024CRS #controlledreleasesociety

Great insights in this whitepaper that don’t only apply to CDx but AI-powered diagnostics. Don’t select your partner just on their ability to develop the diagnostic, but also on their ability to help you commercialize it. Too often there is a lack of adoption because commercialization is an afterthought. #precisionmedicine #diagnostics #artificialintelligence

Roadshow: Arovella Therapeutics ASX: ALA Non-Deal Road Show 3-5 July 2024 Blue Ocean Equities will be hosting Arovella Therapeutics for a non-deal road show. Presenting will be CEO & Managing Director, Michael Baker 3 July - Sydney 4 July - Brisbane 5 July - Melboure Manufacturing and next steps for Arovella are to be discussed at the presentation. If you would like to catch up with Michael please contact me. Arovella has recently achieved a significant milestone by completing process development for its patent protected manufacturing process required for large-scale Good Manufacturing Practice (#GMP) manufacturing of its lead product, ALA-101. This achievement paves the way for Arovella to proceed with engineering and GMP batches to produce material for phase 1 clinical trials. This milestone facilitates Arovella’s pipeline expansion for its CAR-iNKT cell platform. The manufacturing process can be applied to all of Arovella’s future CAR-iNKT cell products, significantly reducing the time required to proceed from proof-of-concept data to clinical manufacture for programs with new CARs.

Advance your practice with BENEV Exosomes technology! 🔬 👉ExoCoBio has invested over $25 million in a cutting-edge GMP facility, guaranteeing the highest quality, stability, and purification of Exosomes. With over 1,000,000 patients treated, 6+ US patents, and an exclusive INCI name, our excellence is unmatched. Shoutout to Michael Gold, MD, FAAD, (@goldskincarecenter) for emphasizing the transformative potential of Exosomes ✨ #benevexosomes #exosomeregenerativecomplex #erc #erc+ #benevskinscience #exosome #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Perfecting Patient Care with Hands-On Simulation Our silicone vasculature models enable physicians, students, and researchers to practice lifesaving procedures before ever touching a patient. Think of it as the surgical equivalent of practicing CPR on a mannequin—you're building confidence and skills without the risk. #MedicalSimulation #HealthcareInnovation #SurgicalTraining #PatientCare #MedTech #MedicalEducation #InterventionalRadiology #CathLabTraining United Biologics, Michael Ghebrial, Kathleen Dae Schilling, Yssa D., Craig Johnson, Melissa Unruh, Alexandra McDaniel

Advance your practice with BENEV Exosomes technology! 🔬 👉ExoCoBio has invested over $25 million in a cutting-edge GMP facility, guaranteeing the highest quality, stability, and purification of Exosomes. With over 1,000,000 patients treated, 6+ US patents, and an exclusive INCI name, our excellence is unmatched. Shoutout to Michael Gold, MD, FAAD, (@goldskincarecenter) for emphasizing the transformative potential of Exosomes ✨ #benevexosomes #exosomeregenerativecomplex #erc #erc+ #benevskinscience #exosome #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Advance your practice with BENEV Exosomes technology! 🔬 👉ExoCoBio has invested over $25 million in a cutting-edge GMP facility, guaranteeing the highest quality, stability, and purification of Exosomes. With over 1,000,000 patients treated, 6+ US patents, and an exclusive INCI name, our excellence is unmatched. Shoutout to Michael Gold, MD, FAAD, (@goldskincarecenter) for emphasizing the transformative potential of Exosomes ✨ #benevexosomes #exosomeregenerativecomplex #erc #erc+ #benevskinscience #exosome #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.